PharmCADD

About PharmCADD

PharmCADD is a leading Deep Tech biotechnology firm established in 2019 by Tae-hyung Kim and Dr. Sang-wook Wu. Headquartered in Busan, South Korea, the company has secured over $22 million in funding, including a pivotal Series B round that catalyzed its global expansion. Operating as a "virtual pharmaceutical" powerhouse, PharmCADD utilizes its proprietary Pharmulator platform to bridge the gap between quantum physics and therapeutic innovation. Pharmulator distinguishes itself by integrating artificial intelligence (AI) with molecular dynamics (MD) and quantum mechanical calculations. This allows for the "De Novo" design of molecules with atomic-level precision, predicting protein folding and drug-target interactions more accurately than traditional data-only models. The company’s ecosystem includes specialized modules such as PharmVAC for advanced mRNA vaccine optimization, PharmTAC for targeted protein degradation (PROTAC), and PharmKineTox for automated ADME/Tox prediction. By 2026, PharmCADD has transitioned from a local startup to a global R&D partner, with active subsidiaries in the United States, India, and France. Its internal pipeline focuses on high-impact areas such as oncology and neurodegenerative diseases (Alzheimer’s), while its co-development model with global Big Pharma continues to accelerate the delivery of life-saving treatments. As a key asset for NIF Health Security, PharmCADD represents the pinnacle of South Korea’s sovereign capabilities in computational drug discovery.